Abstract
Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is presented. Despite treatment with ursodeoxycholic acid and cholestyramine, bilirubin and transaminase levels remained elevated. This case report raises awareness of the difficulty of managing this condition in patients with COVID-19.
Original language | English (US) |
---|---|
Article number | 100116 |
Pages (from-to) | 1-3 |
Number of pages | 3 |
Journal | Journal of Translational Autoimmunity |
Volume | 4 |
Early online date | Aug 31 2021 |
DOIs | |
State | Published - 2021 |
All Science Journal Classification (ASJC) codes
- Infectious Diseases